Research

Bayer, CRISPR Therapeutics to form Gene Editing Joint Venture

Bayer, CRISPR Therapeutics to form Gene Editing Joint Venture

Bayer and CRISPR Therapeutics will join hands to form a joint venture that will carry out research on a new potential gene editing technology. The joint venture will be owned 50% each by both the companies. The German pharmaceutical company will spend 300 million euros during the coming five years on the joint venture. It will also buy the Swiss biotech firm’s shares worth 35 million euros.

Study finds strong evidence of link between antidepressant usage during final two trimesters of pregnancy and autism

Study finds strong evidence of link between antidepressant usage during final two trimesters of pregnancy and autism

According to some of the strongest evidence provided by a new study, using an antidepressant like Prozac, Paxil or Zoloft at the time of the final 2 trimesters of pregnancy could be linked to a higher risk of autism spectrum disorder for the new born.

Pages

Subscribe to RSS - Research